Literature DB >> 17434145

Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3.

Erkang Fei1, Nali Jia, Tao Zhang, Xiaochuan Ma, Hongfeng Wang, Chao Liu, Wei Zhang, Lili Ding, Nobuyuki Nukina, Guanghui Wang.   

Abstract

Machado-Joseph disease (MJD) is a dominant neurodegenerative disorder caused by an expansion of the polyglutamine tract in MJD-1 gene product, ataxin-3. Recently, studies show that phosphorylation of polyglutamine disease proteins, such as huntingtin, ataxin-1 and DRPLA, plays an important role in regulating pathogenesis. However, the kinase that phosphorylates ataxin-3 remains unknown. Here we show that S256 site in ataxin-3 is phosphorylated by GSK 3beta. Moreover, S256A mutant of expanded ataxin-3 forms high molecular weight protein aggregation, whereas S256D mutant and expanded ataxin-3 without mutation on this site are monomeric. The molecular chaperone Hsp70 represses the aggregation of S256A mutant. Our results imply that phosphorylation of serine 256 in ataxin-3 by GSK 3beta regulates ataxin-3 aggregation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434145     DOI: 10.1016/j.bbrc.2007.03.160

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease.

Authors:  Yan Wang; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

Review 2.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 3.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

4.  Co-chaperone HSJ1a dually regulates the proteasomal degradation of ataxin-3.

Authors:  Xue-Chao Gao; Chen-Jie Zhou; Zi-Ren Zhou; Yu-Hang Zhang; Xue-Ming Zheng; Ai-Xin Song; Hong-Yu Hu
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

5.  PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Authors:  Na-Li Jia; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

6.  Casein kinase 2 interacts with and phosphorylates ataxin-3.

Authors:  Rui-Song Tao; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-10       Impact factor: 5.203

Review 7.  Protein truncation as a common denominator of human neurodegenerative foldopathies.

Authors:  Santosh Jadhav; Norbert Zilka; Michal Novak
Journal:  Mol Neurobiol       Date:  2013-03-21       Impact factor: 5.590

8.  Trinucleotide repeats: a structural perspective.

Authors:  Bruno Almeida; Sara Fernandes; Isabel A Abreu; Sandra Macedo-Ribeiro
Journal:  Front Neurol       Date:  2013-06-20       Impact factor: 4.003

9.  Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.

Authors:  Mário N Laço; Luisa Cortes; Sue M Travis; Henry L Paulson; A Cristina Rego
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 10.  Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code.

Authors:  Yanfeng Wang; Feng Wang
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.